Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Birth defects research. Clinical and molecular teratology

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/BDRA.20184PMID 16206282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Teratogen update: evaluation of the reproductive and developmental risks of caffeine.

  2001cited by this paper
• Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures.

  1999cited by this paper
• Prenatal exposure to sex hormones: a case-control study.

  1998cited by this paper
• A changing pattern in the association of oral contraceptives and the different groups of congenital limb deficiencies.

  1995cited by this paper
• Bringing scholarship to the courtroom: the Daubert decision and its impact on the Teratology Society.

  1995cited by this paper
• FETAL GENITAL EFFECTS OF FIRST‐TRIMESTER SEX HORMONE EXPOSURE: A META‐ANALYSIS

  1995cited by this paper
• Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen.

  1995cited by this paper
• Biological Factors Related to Male Mediated Reproductive and Developmental Toxicity

  1994cited by this paper
• Cardiovascular birth defects and prenatal exposure to female sex hormones: importance of utilizing proper epidemiological methods and teratologic principles.

  1994cited by this paper
• Congenital malformation case reports: the editor's and reviewer's dilemma.

  1993cited by this paper
• What is the relationship between birth defects and pregnancy bleeding? New perspectives provided by the NICHD workshop dealing with the association of chorionic villous sampling and the occurrence of limb reduction defects.

  1993cited by this paper
• Report of National Institute of Child Health and Human Development Workshop on Chorionic Villus Sampling and Limb and Other Defects, October 20, 1992.

  1993cited by this paper
• Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse.

  1993cited by this paper
• Reproductive and teratologic effects of electromagnetic fields.

  1993cited by this paper
• Report of National Institute of Child Health and Human Development Workshop on Chorionic Villus Sampling and Limb and Other Defects, October 20, 1992.

  1993cited by this paper
• The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.

  1992cited by this paper
• Cardiovascular birth defects and prenatal exposure to female sex hormones: a reevaluation of data reanalysis from a large prospective study.

  1992cited by this paper
• Analyses and reanalyses of epidemiologic data: learning lessons and maintaining perspective.

  1992cited by this paper
• Analyses and reanalyses of epidemiologic data: learning lessons and maintaining perspective.

  1992cited by this paper
• Medical sonography: reproductive effects and risks.

  1991cited by this paper
• Effects of 17‐hydroxyprogesterone caproate (17‐OHPC) administration to pregnant squirrel monkeys (Saimiri boliviensis boliviensis)

  1991cited by this paper
• Use of Prescription Drugs in the First Trimester and Congenital Malformations

  1991cited by this paper
• The authors' response to hogue

  1991cited by this paper
• Invited commentary: the contraceptive technology tightrope.

  1991cited by this paper
• In utero exposure to steroid contraceptives and survival during infancy.

  1991cited by this paper
• In utero exposure to steroid contraceptives and outcome of pregnancy.

  1991cited by this paper
• Relationship between uterine vascular clamping, vascular disruption syndrome, and cocaine teratogenicity.

  1990cited by this paper
• Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate.

  1990cited by this paper
• Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies.

  1990cited by this paper
• Characterization of cytosolic glucocorticoid receptor of fetal rat epiphyseal chondrocytes.

  1990cited by this paper
• Kudos to the Food and Drug Administration: reversal of the package insert warning for birth defects for oral contraceptives.

  1989cited by this paper
• Medroxyprogesterone Acetate Therapy in Early Pregnancy Has No Apparent Fetal Effects

  1989cited by this paper
• Developmental effects of progesterone and its derivatives.

  1988cited by this paper
• Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects?

  1988cited by this paper
• Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects.

  1988cited by this paper
• Labeling guidance for combination oral contraceptives

  1988cited by this paper
• Ethnic Variation in Blood Pressure among Preadolescent Children

  1988cited by this paper
• Steroid contraceptive use and pregnancy outcome.

  1988cited by this paper
• Estrogen and progesterone receptors in the organs of prenatal cynomolgus monkey and laboratory mouse.

  1986cited by this paper
• Congenital limb reduction deformities and use of oral contraceptives.

  1986cited by this paper
• The risk of fetal anomalies as a result of progesterone therapy during pregnancy.

  1986cited by this paper
• Exogenous sex hormone exposure and the risk for VACTERL association.

  1986cited by this paper
• Fetal malformations following progesterone therapy during pregnancy: a preliminary report.

  1985cited by this paper
• Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancy.

  1985cited by this paper
• Decreased abortions in HMG-induced pregnancies with prophylactic progesterone therapy.

  1985cited by this paper
• Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis).

  1985cited by this paper
• Morphological and biochemical aspects of monofunctional phosphoramide mustard teratogenicity in rat embryos cultured in vitro.

  1985cited by this paper
• Methods of evaluating the alleged teratogenicity of environmental agents.

  1985cited by this paper
• Early luteal serum progesterone concentrations are higher in pregnancy cycles.

  1985cited by this paper
• Teratogenicity of Progestogens Given During the First Trimester of Pregnancy

  1985cited by this paper
• Progesterone therapy: benefit versus risk.

  1985cited by this paper
• Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus).

  1985cited by this paper
• Changes in total and free concentrations of steroid hormones in the plasma of women throughout pregnancy: effects of medroxyprogesterone acetate in the first trimester.

  1985cited by this paper
• Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception.

  1985cited by this paper
• Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.

  1985cited by this paper
• Teratogen update: clinical aspects of thalidomide embryopathy--a continuing preoccupation.

  1985cited by this paper
• A multivariate analysis of the risk indicators of reduction limb defects.

  1984cited by this paper
• Comment: Teratogenicity of progestational agents

  1984cited by this paper
• Teratogenicity of progestational agents.

  1984cited by this paper
• Infants with congenital limb reduction registered in the Swedish Register of Congenital Malformations.

  1984cited by this paper
• Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data.

  1984cited by this paper
• The effect of medroxyprogesterone acetate (Depo-Provera) on prenatal development in the baboon (Papio anubis): a preliminary study.

  1984cited by this paper
• Teratogenicity Of progestational agents: Response to the Drs. Nora

  1984cited by this paper
• Medroxyprogesterone in in-vitro fertilisation.

  1983cited by this paper
• Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts).

  1983cited by this paper
• Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice.

  1983cited by this paper
• Lack of association between contraceptive usage and congenital malformations in offspring.

  1983cited by this paper
• Sex hormones and non-genital organ birth defects.

  1983cited by this paper
• Teratogenic effects of Silastic intrauterine devices in the rat with or without added medroxyprogesterone acetate.

  1983cited by this paper
• Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations.

  1983cited by this paper
• An aetiological evaluation of increased occurrence of congenital limb reduction abnormalities in Hungary, 1975-1978.

  1983cited by this paper
• Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts).

  1983cited by this paper
• The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?

  1983cited by this paper
• Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (Macaca mulatta).

  1983cited by this paper
• Medroxyprogesterone in in-vitro fertilisation.

  1983cited by this paper
• Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. II. Cyproterone acetate and medroxyprogesterone acetate treatment before implantation in vivo and in vitro.

  1982cited by this paper
• Evaluation of the use of prolution‐depot (hydroxyprogesterone hexanoate) in early pregnancy

  1982cited by this paper
• Vascular pathogenesis of transverse limb reduction defects.

  1982cited by this paper
• The irresponsible expert witness: a failure of biomedical graduate education and professional accountability.

  1982cited by this paper
• Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. I.

  1982cited by this paper
• The effect of female sex hormones on fetal development and infant health.

  1981cited by this paper
• Sex hormones in pregnancy.

  1981cited by this paper
• The return of fertility following discontinuation of oral contraceptives in Thailand.

  1981cited by this paper
• ORAL CONTRACEPTIVES AND BIRTH DEFECTS

  1981cited by this paper
• Are female sex hormones teratogenic?

  1981cited by this paper
• The relationship between hormonal pregnancy tests and congenital anomalies: a prospective study.

  1981cited by this paper
• The Depo-Provera debate. Commentary on the article "Depo-Provera, a critical analysis".

  1981cited by this paper
• Sex hormones in pregnancy.

  1981cited by this paper
• Teratogenic hazards of oral contraceptives analyzed in a national malformation register.

  1981cited by this paper
• OUTCOME OF PREGNANCIES COMPLICATED BY EARLY VAGINAL BLEEDING

  1980cited by this paper
• Maternal hormone therapy and congenital heart disease.

  1980cited by this paper
• Ectopic pregnancy and myoma uteri: teratogenic effects and maternal characteristics.

  1980cited by this paper
• Cardiovascular birth defects and antenatal exposure to female sex hormones

  1980cited by this paper
• ORAL CONTRACEPTION AND CONGENITAL ABNORMALITIES

  1980cited by this paper
• Oral contraceptives and birth defects.

  1980cited by this paper
• Congenital abnormalities and hormones during pregnancy: a clinical review.

  1980cited by this paper
• Ectopic pregnancy and myoma uteri: Teratogenic effects and maternal characteristics

  1980cited by this paper
• Pectoralis major muscle defect and Poland complex.

  1979cited by this paper
• Biochemical diagnosis of pralactinoma.

  1979cited by this paper
• Thalidomide Dysmelia in Japan

  1979cited by this paper

• Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization

  2025influential citation
• A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis.

  2022cites this paper
• Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference

  2021cites this paper
• Maternal risk factors for congenital limb deficiencies: A population-based case-control study.

  2021cites this paper
• CONGENITAL LOWER LIMB DEFICIENCIES IN FINLAND

  2020influential citation
• Preterm birth prevention.

  2020cites this paper
• Clinical Teratology

  2019cites this paper
• Use of progesterone supplement therapy for prevention of preterm birth: review of literatures

  2017cites this paper
• Role of Progesterone in Miscarriage

  2016cites this paper
• EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations

  2016cites this paper
• Progesterone Treatment for Prevention of Preterm Birth

  2016cites this paper
• Prevalence of prescribing in pregnancy using the Irish primary care research network: a pilot study

  2015cites this paper
• Assessment of historical evidence on Primodos and congenital malformations – a synopsis Background In January 2014

  2014cites this paper
• Counseling women and men regarding exposures to reproductive and developmental toxicants before conception or women during pregnancy.

  2014cites this paper
• Schwangerschaften während der Anwendung kontrazeptiver Methoden - Eine Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands der Frauenärzte (BVF) e.V.

  2013influential citation
• The Rebirth of Progesterone in the Prevention of Preterm Labor

  2013cites this paper
• Chapter 36 – Clinical Teratology

  2013cites this paper
• A practical guide to contraception3: Traditional methods, sterilisation and emergency contraception

  2013cites this paper
• A practical guide to contraception2

  2013cites this paper
• A practical guide to contraception. Part 2: Long-acting reversible methods

  2013cites this paper
• Progesterone in Human Pregnancy and Parturition

  2012cites this paper
• Multigeneration reproductive study of hydroxyprogesterone caproate (HPC) in the rat: laboratory results and clinical significance.

  2012cites this paper
• Is There Evidence for Aetiologically Distinct Subgroups of Idiopathic Congenital Talipes Equinovarus? A Case-Only Study and Pedigree Analysis

  2011cites this paper
• Health technology assessment in maternal and perinatal medicine : delphi survey of practice, systematic reviews of evidence and meta analyses

  2011cites this paper
• Evaluation of the Reproductive and Developmental Risks of Caffeine

  2011cites this paper
• Clinical management of the short cervix.

  2011cites this paper
• Medication use in early pregnancy‐prevalence and determinants of use in a prospective cohort of women

  2010cites this paper
• Genetics, Epidemiology, and Counseling

  2009cites this paper
• Prematurity prevention: the role of progesterone

  2009cites this paper
• Prevention of preterm birth based on short cervix: progesterone.

  2009cites this paper
• Pregnancy outcome after exposure to oral contraceptives during the periconceptional period

  2008cites this paper
• Depot-medroxyprogesterone acetate: an update

  2008cites this paper
• Drugs in infertility and fetal safety.

  2008cites this paper
• Schwangerschaften unter verschiedenen kontrazeptiven Methoden

  2008cites this paper
• 2.15 – Hormones

  2007cites this paper
• How does a physician avoid prescribing drugs and medical procedures that have reproductive and developmental risks?

  2007cites this paper
• Progesterone and the risk of preterm birth among women with a short cervix.

  2007cites this paper
• Embryo–fetal toxicity signals for 17α-hydroxyprogesterone caproate in high-risk pregnancies: A review of the non-clinical literature for embryo–fetal toxicity with progestins

  2007influential citation
• Evaluating emerging issues in epidemiology.

  2007cites this paper
• The effects of high dose progesterone on neural tube development in early chick embryos.

  2006cites this paper
• Progesterone for the prevention of preterm birth: a critical evaluation of evidence.

  2006cites this paper
• Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey.

  2006cites this paper
• "Natural" progesterone: information on fetal effects.

  2006cites this paper
• MODERN TRENDS

  year unknowncites this paper